Investment Thesis
Pfizer demonstrates operational strength with healthy 21.9% operating margins and solid free cash flow generation of $2.2B, but is hindered by declining revenue (-1.6% YoY), stalled net income growth, and critically poor capital efficiency reflected in 3.0% ROE and 1.3% ROA. High debt burden combined with low cash reserves and weak quick ratio create vulnerability despite operational profitability.
Strengths
- Strong operating margin of 21.9% and net margin of 18.6% demonstrate pricing power and operational efficiency
- Positive free cash flow of $2.2B with 15.1% FCF margin provides financial flexibility and dividend capacity
- Moderate debt-to-equity ratio of 0.67x and interest coverage of 4.7x indicate manageable debt service obligations
Risks
- Revenue declining 1.6% YoY with flat net income growth and declining EPS (-3.5%) signals top-line pressure and margin compression
- Extremely poor capital efficiency with ROE of 3.0% and ROA of 1.3% indicates significant capital destruction despite operational profitability
- High debt load of $60.6B relative to minimal cash position of $1.7B and quick ratio below 1.0 (0.94x) constrains financial flexibility
Key Metrics to Watch
- Revenue growth trajectory and return to positive growth
- Return on equity improvement path - currently unacceptable at 3.0%
- Cash position and debt reduction strategy relative to operational cash flow
Financial Metrics
Revenue
14.5B
Net Income
2.7B
EPS (Diluted)
$0.47
Free Cash Flow
2.2B
Total Assets
207.6B
Cash
1.7B
Profitability Ratios
Gross Margin
N/A
Operating Margin
21.9%
Net Margin
18.6%
ROE
3.0%
ROA
1.3%
FCF Margin
15.1%
Balance Sheet & Liquidity
Current Ratio
1.25x
Quick Ratio
0.94x
Debt/Equity
0.67x
Debt/Assets
56.5%
Interest Coverage
4.75x
Long-term Debt
60.6B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:11:41.897246 |
Data as of: 2026-03-29 |
Powered by Claude AI